Author/Authors :
Hajigholami, Samira Department of Genetics - Faculty of Biological Sciences - Tarbiat Modares University, Tehran, Iran , Veisi Malekshahi, Ziba Department of Medical Biotechnology - School of Advanced Medical Sciences and Technologies - Tehran University of Medical Sciences, Tehran, Iran , Bodaghabadi, Narges Department of Genetics - Faculty of Biological Sciences - Tarbiat Modares University, Tehran, Iran , Najafi, Farhod Department of Resin and Additives - Institutes for Color Sciences and Technology, Tehran, Iran , Shirzad, Hadi Department of Medical Genetics - Faculty of Medical Sciences - TarbiatModares University, Tehran, Iran , Sadeghizadeh, Majid Department of Genetics - Faculty of Biological Sciences - Tarbiat Modares University, Tehran, Iran
Abstract :
Tamoxifen is routinely used for treatment of Estrogen-positive breast carcinoma.
Approximately, 50% of patients with metastatic cancer will develop resistance to Tamoxifen.
In this research, Tamoxifen was combined with the anti-cancer compound Curcumin.
Diblocknanopolymer was used to package the new formulation of Curcumin and Tamoxifen.
Anti-cancer efficacy of the obtained compound was evaluated in Tamoxifen-sensitive (TS).
MCF-7, Tamoxifen-resistant (TR) MCF-7 cancer cells and Fibroblast cells. MTT assay was
used to evaluate anti-proliferation and toxicity. Flow cytometry and Annexin-V-FLUOS were
used to assay anti-proliferation and induction of apoptosis respectively. Our results indicate
that the obtained nano-compound is less toxic to normal cells compared to Tamoxifen alone,
and has higher anti-proliferation and pro-apoptotic activity on TS-MCF-7 and TR-MCF-7.
The nanopolymer reduces the Tamoxifen toxicity in normal cells and counters the developed
resistance to the drug in cancer cells.
Keywords :
Polymer Nano-carrier , Tamoxifen , Curcumin , Breast Cancer
